The drug, a nasal spray, was touted by the drugmaker as a powerful new tool to fight intractable depression because the spray acts within hours, rather than weeks or months as current antidepressants do. But a component of the drug, the anesthetic ketamine, a once-popular party drug known as Special K, has sparked concern about its long-term use. Other medical experts questioned its true effectiveness.
President Trump said the drug has shown a positive effect in early testing, and he is optimistic it can help prevent veterans suicide.
“This is a form of a stimulant where, if someone is really in trouble from the standpoint of suicide, it can do something,” President Trump said ahead of his remarks at a veteran’s national convention, according to Military Times. “It’s pretty well known, it just came out. We have calls in to Johnson & Johnson now, we’ve been talking to them for two months on buying a lot of it.”
Earlier this year, reports surfaced that President Trump was pushing VA officials for quicker adoption of Spravato as a mental health treatment. In June a VA medical advisory panel declined to put the drug on its list of VA-approved medications. The move doesn’t ban the use of the drug, but requires physicians to justify why patients need the treatment.
Read the full report here.
More articles on pharmacy:
FDA approves AbbVie’s $59K rheumatoid arthritis drug
Teva launches generic version of EpiPen for kids
American Regent boosted price of essential hospital product by 1,300%
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
